海昇药业
(920656)
| 流通市值：11.93亿 | | | 总市值：14.61亿 |
| 流通股本：8162.86万 | | | 总股本：1.00亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 141,142,471.8 | 65,642,203.39 | 220,598,316.5 | 163,844,572.3 |
| 营业总成本 | 90,517,235.86 | 44,276,393.9 | 149,016,474.19 | 111,159,132.03 |
| 其他经营收益 | | | | |
| 营业利润 | 54,610,428.86 | 23,218,504.74 | 80,169,930.18 | 56,662,633.72 |
| 利润总额 | 54,545,206.86 | 23,218,504.74 | 80,188,501.44 | 56,681,204.98 |
| 净利润 | 47,021,107.42 | 20,092,479.96 | 69,456,983.52 | 49,047,356.7 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 47,021,107.42 | 20,092,479.96 | 69,456,983.52 | 49,047,356.7 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 510,820,033.25 | 520,939,008.84 | 503,791,918.57 | 488,806,422.01 |
| 非流动资产: | | | | |
| 非流动资产合计 | 230,521,673.38 | 229,448,568.79 | 233,084,127.39 | 216,906,334.3 |
| 资产总计 | 741,341,706.63 | 750,387,577.63 | 736,876,045.96 | 705,712,756.31 |
| 流动负债: | | | | |
| 流动负债合计 | 25,357,066.59 | 21,330,079.88 | 27,976,325.99 | 17,232,710.14 |
| 非流动负债: | | | | |
| 非流动负债合计 | 5,100,063.01 | 5,277,618.23 | 5,455,173.45 | 5,781,310.25 |
| 负债合计 | 30,457,129.6 | 26,607,698.11 | 33,431,499.44 | 23,014,020.39 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 710,884,577.03 | 723,779,879.52 | 703,444,546.52 | 682,698,735.92 |
| 股东权益合计 | 710,884,577.03 | 723,779,879.52 | 703,444,546.52 | 682,698,735.92 |
| 负债和股东权益合计 | 741,341,706.63 | 750,387,577.63 | 736,876,045.96 | 705,712,756.31 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 94,984,923.1 | 35,462,235.82 | 147,249,579.77 | 99,635,395.41 |
| 经营活动现金流出小计 | 67,444,641.83 | 30,977,133.2 | 111,920,876.87 | 80,705,498.54 |
| 经营活动产生的现金流量净额 | 27,540,281.27 | 4,485,102.62 | 35,328,702.9 | 18,929,896.87 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 2,049,666,868.06 | 1,002,062,125.75 | 2,521,984,077.42 | 1,834,111,195.97 |
| 投资活动现金流出小计 | 1,996,606,476.79 | 950,372,837.37 | 2,582,952,404.7 | 2,202,265,115.09 |
| 投资活动产生的现金流量净额 | 53,060,391.27 | 51,689,288.38 | -60,968,327.28 | -368,153,919.12 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | - | - | - |
| 筹资活动现金流出小计 | 40,000,000 | - | 39,698,100 | 39,698,100 |
| 筹资活动产生的现金流量净额 | -40,000,000 | - | -39,698,100 | -39,698,100 |
| 汇率变动对现金及现金等价物的影响 | -1,573,262.05 | -732,110.49 | -696,089.16 | -36,256.69 |
| 现金及现金等价物净增加额 | 39,027,410.49 | 55,442,280.51 | -66,033,813.54 | -388,958,378.94 |
| 期末现金及现金等价物余额 | 419,637,677.44 | 436,052,547.46 | 380,610,266.95 | 57,685,701.55 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 39,027,410.49 | - | -66,033,813.54 | - |